1
Annex 3
Annex 3. Potentially overlapping toxicities of antiretrovirals and anti-tuberculosis agents (including first-line anti-tuberculosis agents)
Potential toxicity Antiretroviral therapy Anti-tuberculosis therapy Peripheral neuropathy stavudine cycloserine
didanosine isoniazid
ethambutol
fluoroquinolones
streptomycin
kanamycin
amikacin
capreomycin
viomycin
ethionamide/prothionamide
linezolid
Psychiatric symptoms efavirenz cycloserine
isoniazid
fluoroquinolones
ethionamide/prothionamide
Hepatitis nevirapine pyrazinamide
ritonavir-boosted protease
inhibitors isoniazid
efavirenz rifampicin/rifabutin
etravirine p-aminosalicylic acid
maraviroc ethionamide/prothionamide
fluoroquinolones
WHO/HTM/TB/2011.6c
2
Annex 3
Annex 3 (continued)
Potential toxicity Antiretroviral therapy Anti-tuberculosis therapy Gastrointestinal intolerance
zidovudine ethionamide/prothionamide protease inhibitors p-aminosalicylic acid
didanosine pyrazinamide
isoniazid
rifampicin
ethambutol
clofazimine
Renal toxicity
tenofovir streptomycin
indinavir kanamycin
capreomycin
amikacin
viomycin
rifampicin Bone marrow toxicity zidovudine linezolid
rifampicin/rifabutin Lactic acidosis
stavudine linezolid
didanosine
zidovudine
Stevens–Johnson syndrome
nevirapine thioacetazone
efavirenz cycloserine
etravirine linezolid
ethambutol
streptomycin
Arrhythmias / QT prolongation
atazanavir/ritonavir fluoroquinolones saquinavir/ritonavir
lopinavir/ritonavir
Rash / pruritus nevirapine rifampicin/rifabutin
efavirenz pyrazinamide
etravirine
abacavir